Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network

被引:0
|
作者
Conover, Mitchell M. [1 ,2 ]
Albogami, Yasser [1 ,3 ]
Hardin, Jill [1 ,2 ]
Reich, Christian G. [1 ,4 ]
Ostropolets, Anna [1 ,2 ,5 ]
Ryan, Patrick B. [1 ,2 ,5 ]
Observational Hlth Data Sci and Informatics OHDSI Res Network
机构
[1] Observat Hlth Data Sci & Informat, New York, NY 10032 USA
[2] Johnson & Johnson, Observat Hlth Data Analyt, Titusville, NJ 08560 USA
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
[4] IQVIA, Real World Solut, Cambridge, MA USA
[5] Columbia Univ, Dept Biomed Informat, New York, NY USA
关键词
chronic lower respiratory disease; common data model; glucagon-like peptide 1 receptor agonists; pharmacoepidemiology; real world data; real world evidence; reliability; replicability; reproducibility; transparency; REPRODUCIBILITY; CALIBRATION; BALANCE;
D O I
10.1002/pds.70087
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionThe aim of this study is to use observational methods to evaluate reliability of evidence generated by a study of the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) on chronic lower respiratory disease (CLRD) outcomes among Type-2 diabetes mellitus (T2DM) patients.Research Design and MethodsWe independently reproduced a study comparing effects of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4-i) on CLRD outcomes among patients with T2DM and prior CLRD. We reproduced inputs and outputs using the original study data (national administrative claims) and evaluated the robustness of results in comparison to alternate design/analysis decisions. To evaluate generalizability, we applied an analysis protocol and conducted a meta-analysis across a research network that includes a diverse array of populations and data sources. We also produced additional analyses evaluating individual drugs within the GLP-1RA class and CLRD outcomes.ResultsWe confirmed alignment of study inputs and outputs and closely reproduced effect estimates and sensitivity analyses. Adjusted effect estimates were robust to empirical calibration. Network meta-analysis confirmed original findings but indicated weaker effects than originally published. Meta-analysis of drugs within the GLP-1RA class against DPP4-i provided evidence that effects vary within the GLP-1RA class, indicating stronger effects for exenatide and weaker effects of dulaglutide.ConclusionsThis study supports and establishes the reliability of the original study by (1) producing consistent findings in a range of alternate databases and populations, (2) demonstrating effects for multiple drugs within the GLP-1RA class, and (3) independently confirming the reproducibility of the original study and its findings. This reliability evaluation provides the beginnings of a broader framework for using standardized tools and distributed data networks to systematically interrogate the reliability of findings generated using observational data.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Effectiveness of glucagon-like peptide-1 agonists in type 2 diabetes
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (03): : 359 - 360
  • [32] Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes
    Edwards, C. M. B.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (04) : 198 - 201
  • [33] UTILIZATION PATTERNS OF GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES IN FRANCE AND ITALY
    Khare, S.
    Osumili, B.
    Debackere, N.
    Keapoletswe, K.
    Falato, S.
    Raoul, T.
    Coles, B.
    VALUE IN HEALTH, 2023, 26 (12) : S512 - S512
  • [34] The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
    Win L. Yin
    Steve C. Bain
    Thinzar Min
    Diabetes Therapy, 2020, 11 : 835 - 844
  • [35] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
    Katherine A. Lyseng-Williamson
    Clinical Drug Investigation, 2019, 39 : 805 - 819
  • [36] Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Cho, Young Min
    Wideman, Rhonda D.
    Kieffer, Timothy J.
    ENDOCRINOLOGY AND METABOLISM, 2013, 28 (04) : 262 - 274
  • [37] Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella, Raffaella
    Pechtner, Valeria
    Corcos, Antonella
    Consoli, Agostino
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (01)
  • [38] Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development
    Ahren, Bo
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (02) : 196 - 201
  • [39] Glucagon-like Peptide-1 Receptor Agonists Prescribing Patterns in Youth with Type 2 Diabetes
    Bensignor, Megan
    Kelly, Aaron
    Wolfe, Jack
    Rudser, Kyle
    Arslanian, Silva
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 1): : 81 - 82
  • [40] Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
    Watchorn, David
    O'Shea, Donal
    Butler, Marcus W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (07) : 923 - 924